Skip to content

Regenerative Medicine and Stem Cell-Based Interventions for Inner Ear Trauma, Tinnitus, and Sensorineural Hearing Loss

Truway Health Inner Ear Regeneration & Hearing Restoration Trial

Status
Enrolling by invitation
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07472023
Acronym
HEAR-RESTORE
Enrollment
120
Registered
2026-03-16
Start date
2026-03-08
Completion date
2099-03-08
Last updated
2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acoustic Trauma, Inner Ear Injury, Noise-Induced Hearing Loss, Sensorineural Hearing Loss, Sudden Hearing Loss, Tinnitus, Vestibular Dysfunction

Keywords

Hearing Loss, Inner Ear Regeneration, Cochlear Hair Cell Regeneration, Audiometry, Stem Cell Therapy, Regenerative Medicine, Tinnitus Treatment, Auditory Nerve Repair, Cochlear Injury, Hearing Restoration

Brief summary

The HEAR-RESTORE study is an exploratory clinical research program designed to evaluate new diagnostic and regenerative approaches for individuals experiencing inner ear injury, tinnitus, and temporary or permanent hearing loss. Inner ear disorders can result from acoustic trauma, infections, inflammation, or other conditions that affect the cochlea, auditory nerve, or vestibular system. These conditions may lead to muffled hearing, ringing in the ears (tinnitus), balance disturbances, or reduced hearing sensitivity. The purpose of this study is to better understand how inner ear injuries develop and to evaluate potential treatments that may support hearing recovery or protect auditory function. Participants will undergo comprehensive ear and hearing evaluations including audiometry, speech recognition testing, tympanometry, and other diagnostic assessments used in audiology and otolaryngology. These tests help measure hearing thresholds, ear pressure, and auditory nerve responses. The study may also explore emerging regenerative medicine strategies aimed at restoring inner ear function. These approaches may include investigational therapies designed to promote repair of cochlear hair cells, reduce inflammation in the inner ear, or support neural recovery in the auditory pathway. Research may include evaluation of regenerative biological therapies, stem cell-based approaches, and other experimental technologies intended to support recovery of hearing or reduce symptoms such as tinnitus. Participants will be monitored over time to assess hearing outcomes, safety, and changes in auditory function. Study assessments may include repeat audiology tests, imaging studies, symptom questionnaires, and other clinical measurements used to track hearing health. The results of this research may contribute to improved diagnostic methods and potential future treatments for individuals with hearing loss or inner ear disorders.

Detailed description

Inner ear disorders are a major cause of hearing impairment worldwide and may result from a variety of causes including acoustic trauma, infections, inflammatory processes, vascular compromise, or degenerative conditions affecting the cochlea and auditory nerve. Damage to sensory hair cells within the cochlea is a common mechanism leading to sensorineural hearing loss and tinnitus. In many cases, these cells do not regenerate naturally in humans, resulting in persistent hearing impairment. The HEAR-RESTORE study is a translational research program designed to investigate diagnostic, monitoring, and investigational therapeutic approaches for individuals experiencing inner ear injury, tinnitus, and temporary or permanent hearing loss. The study focuses on improving the understanding of cochlear injury mechanisms and evaluating potential regenerative and protective strategies that may support auditory recovery. Participants enrolled in the study will undergo comprehensive otologic and audiologic evaluations. Baseline assessments will include a detailed clinical history, otoscopic examination, and standardized hearing tests. Audiologic evaluations will include pure-tone audiometry to determine hearing thresholds across multiple frequencies, speech recognition testing, tympanometry to evaluate middle ear pressure and compliance, and otoacoustic emissions testing to assess cochlear hair cell function. Additional neuro-auditory testing such as auditory brainstem response (ABR) testing may be performed to evaluate auditory nerve conduction and central auditory pathways. The study may also include advanced diagnostic tools such as vestibular function testing, imaging studies of the inner ear structures, and digital symptom monitoring to assess tinnitus severity and functional hearing ability in daily environments. These assessments allow researchers to characterize patterns of hearing impairment and track changes over time. In addition to diagnostic assessments, the study may explore investigational strategies aimed at supporting inner ear repair and auditory recovery. Research areas of interest include regenerative medicine approaches that aim to restore or protect cochlear hair cells and auditory neurons. Investigational concepts may include biological therapies designed to stimulate endogenous repair pathways, neuroprotective agents that reduce inflammatory damage in the cochlea, and emerging regenerative technologies intended to support cellular repair within the inner ear environment. The research program may also investigate stem cell-based approaches and other regenerative biological strategies designed to promote repair of damaged auditory structures. These approaches are being explored in early-stage research as potential methods to support regeneration of cochlear hair cells or improve neural signaling in the auditory system. Any investigational therapies evaluated in this study will be assessed primarily for safety and feasibility, with careful monitoring of auditory outcomes and adverse events. Participants may be followed longitudinally to evaluate hearing outcomes, symptom progression, and overall auditory function. Follow-up evaluations may include repeat audiometric testing, tinnitus symptom scoring, vestibular assessments, and patient-reported outcome measures. These data will allow researchers to evaluate whether investigational approaches are associated with improvements in hearing thresholds, speech recognition ability, or reductions in tinnitus severity. The study will also collect observational data related to potential risk factors for inner ear injury, including noise exposure, environmental factors, medication history, and prior medical conditions that may affect auditory health. These data may help improve understanding of how hearing loss develops and identify populations that may benefit from early intervention. The results of the HEAR-RESTORE study are expected to contribute to the development of improved diagnostic frameworks and future therapeutic strategies for individuals with inner ear disorders. By combining comprehensive audiologic evaluation with emerging regenerative research approaches, this program aims to advance scientific understanding of hearing restoration and support the development of new treatments for hearing loss and tinnitus. The findings from this research may inform future clinical trials, guide development of regenerative therapies for the inner ear, and support improved clinical management of patients experiencing hearing impairment due to injury or disease affecting the auditory system.

Interventions

OTHERAudiologic Monitoring

Standard audiologic testing including pure-tone audiometry, speech recognition testing, tympanometry, and auditory function monitoring performed at scheduled study visits.

DRUGInvestigational Regenerative Pharmacologic Therapy

Investigational pharmacologic agents designed to support inner ear repair or protect cochlear hair cells following injury.

BIOLOGICALStem Cell Regenerative Therapy

Investigational regenerative therapy involving stem cell-based approaches intended to support repair of cochlear hair cells and auditory neural pathways.

COMBINATION_PRODUCTCombination Regenerative Therapy

Investigational combination therapy involving regenerative pharmacologic agents and biological therapies designed to promote recovery of auditory function.

Sponsors

Truway Health, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Masking description

This study is conducted as an open-label exploratory trial in which both investigators and participants are aware of the assigned interventions. Audiometric outcome measurements will follow standardized testing protocols to ensure consistent assessment.

Intervention model description

Participants will be assigned to parallel study arms evaluating diagnostic monitoring, regenerative medicine approaches, and investigational therapies designed to support recovery of inner ear function following injury or hearing loss. Outcomes will be compared across groups using standardized audiologic assessments.

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

Adults aged 18-75 years Clinical diagnosis of sensorineural hearing loss, tinnitus, or inner ear injury Hearing threshold ≥25 dB HL at one or more audiometric frequencies Ability to complete audiometric testing and follow study procedures Ability to provide informed consent

Exclusion criteria

Active middle ear infection History of cochlear implant surgery Known retrocochlear pathology Participation in experimental hearing regeneration therapy within 12 months Known pregnancy at time of enrollment Any medical condition that may interfere with study participation or safety

Design outcomes

Primary

MeasureTime frameDescription
Change in Pure-Tone Audiometry Hearing Threshold (dB HL)Baseline to 6 monthsChange in hearing threshold levels measured in decibels hearing level (dB HL) across standard audiometric frequencies (0.25-8 kHz) using calibrated pure-tone audiometry. Lower dB HL values indicate improved auditory sensitivity.

Secondary

MeasureTime frameDescription
Speech Recognition Score (Word Recognition Percentage)Baseline to 6 monthsSpeech recognition ability measured using standardized word recognition testing (e.g., NU-6 word lists). Scores range from 0-100%, with higher scores indicating better speech discrimination ability.
Change in Tinnitus Functional Index (TFI) ScoreBaseline to 6 monthsPatient-reported tinnitus severity measured using the Tinnitus Functional Index (TFI). Scores range from 0-100, with higher scores indicating greater tinnitus severity. A decrease in score reflects clinical improvement.
Safety and Adverse Event MonitoringBaseline through 12 monthsThe incidence and severity of adverse events related to investigational interventions will be monitored throughout the study period. Safety outcomes will include clinical observations, audiologic findings, and any reported complications.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORGavin C Solomon, CEO

Truway Health, Inc.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 17, 2026